Work

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Year: 2008

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.236.236

Authors: Arnold S. Freedman, Sattva Neelapu, Craig R Nichols, Michael Robertson, Benjamin Djulbegovic, Jane N. Winter, Daniel Gold, John Bender, Morgan Stewart, Richard G. Ghalie, Paul A. Hamlin

Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Providence Portland Medical Center, Moffitt Cancer Center, Northwestern University, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2549365404

FWCI: 2.134

Cites:

Cited by: 11

Related to: 10